New Insights into antimetastatic and antiangiogenic effects of cannabinoids

International Review of Cell and Molecular Biology

Volumn 314, Issue , 2015, Pages 43-116

  Ramer, Robert ^a   Hinz, Burkhard ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Angiogenesis; Cancer; Cannabinoids; Metastasis; Tumor cell invasion

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2 METHYL ARACHIDONYL 2' FLUORO ETHYLAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; ANTINEOPLASTIC AGENT; ARACHIDONYL 2' CHLOROETHYLAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID DERIVATIVE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXANABINOL; ENDOCANNABINOID; HU 331; METHANANDAMIDE; O 1663; PALMIDROL; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CANNABIS SMOKING; CELL CYCLE PROGRESSION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; DRUG MECHANISM; DRUG RESISTANCE; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNOSURVEILLANCE; METASTASIS; METASTASIS INHIBITION; NONHUMAN; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SMOKING; TUMOR CELL; TUMOR GROWTH; ANIMAL; CELL DIFFERENTIATION; CELL MOTION; DRUG EFFECTS; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CANNABINOIDS; CELL DIFFERENTIATION; CELL MOVEMENT; ENDOTHELIAL CELLS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84921602739     PISSN: 19376448     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.ircmb.2014.10.005     Document Type: Article

References (320)

1. Ahn G.O., Brown J.M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008, 13:193-205.
2. Ahn K., Johnson D.S., Fitzgerald L.R., Liimatta M., Arendse A., Stevenson T., Lund E.T., Nugent R.A., Nomanbhoy T.K., Alexander J.P., Cravatt B.F. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 2007, 46:13019-13030.
3. Albert D.M., Ryan L.M., Borden E.C. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch. Ophthalmol. 1996, 114:107-108.
4. Aldington S., Harwood M., Cox B., Weatherall M., Beckert L., Hansell A., Pritchard A., Robinson G., Beasley R. Cannabis and Respiratory Disease Research Group. Cannabis use and risk of lung cancer: a case-control study. Eur. Respir. J. 2008, 31:280-286.
5. Alexander J.P., Cravatt B.F. Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem. Biol. 2005, 12:1179-1187.
6. Anday J.K., Mercier R.W. Gene ancestry of the cannabinoid receptor family. Pharmacol. Res. 2005, 52:463-466.
7. Andradas C., Caffarel M.M., Perez-Gomez E., Salazar M., Lorente M., Velasco G., Guzman M., Sanchez C. The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 2011, 30:245-252.
8. Arany Z., Foo S.Y., Ma Y., Ruas J.L., Bommi-Reddy A., Girnun G., Cooper M., Laznik D., Chinsomboon J., Rangwala S.M., Baek K.H., Rosenzweig A., Spiegelman B.M. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 2008, 451:1008-1012.
9. Arnold J.C., Hone P., Holland M.L., Allen J.D. CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells. Pharmacol. Rep. 2012, 64:751-757.
10. Baker D., Pryce G., Davies W.L., Hiley C.R. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol. Sci. 2006, 27:1-4.
11. Balas L., Durand T., Saha S., Johnson I., Mukhopadhyay S. Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity. J. Med. Chem. 2009, 52:1005-1017.
12. Barsky S.H., Roth M.D., Kleerup E.C., Simmons M., Tashkin D.P. Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco. J. Natl. Cancer Inst. 1998, 90:1198-1205.
13. Benita Y., Kikuchi H., Smith A.D., Zhang M.Q., Chung D.C., Xavier R.J. An integrative genomics approach identifies hypoxia inducible factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res. 2009, 37:4587-4602.
14. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000, 2:737-744.
15. Besner G.E., Whelton D., Crissman-Combs M.A., Steffen C.L., Kim G.Y., Brigstock D.R. Interaction of heparin-binding EGF-like growth factor (HB-EGF) with the epidermal growth factor receptor: modulation by heparin, heparinase, or synthetic heparin-binding HB-EGF fragments. Growth factors 1992, 7:289-296.
16. Bifulco M., Laezza C., Pisanti S., Gazzerro P. Cannabinoids and cancer: pros and cons of an antitumour strategy. Br. J. Pharmacol. 2006, 148:123-135.
17. Bifulco M., Laezza C., Portella G., Vitale M., Orlando P., De Petrocellis L., Di Marzo V. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J. 2001, 15:2745-2747.
18. Bifulco M., Laezza C., Valenti M., Ligresti A., Portella G., Di Marzo V. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J. 2004, 18:1606-1608.
19. Bisogno T., Hanus L., De Petrocellis L., Tchilibon S., Ponde D.E., Brandi I., Moriello A.S., Davis J.B., Mechoulam R., Di Marzo V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 2001, 134:845-852.
20. Bisogno T., Melck D., De Petrocellis L., Bobrov M., Gretskaya N.M., Bezuglov V.V., Sitachitta N., Gerwick W.H., Di Marzo V. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem. Biophys. Res. Commun. 1998, 248:515-522.
21. Blankman J.L., Simon G.M., Cravatt B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 2007, 14:1347-1356.
22. Blazquez C., Carracedo A., Barrado L., Real P.J., Fernandez-Luna J.L., Velasco G., Malumbres M., Guzman M. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 2006, 20:2633-2635.
23. Blazquez C., Casanova M.L., Planas A., Gomez Del Pulgar T., Villanueva C., Fernandez-Acenero M.J., Aragones J., Huffman J.W., Jorcano J.L., Guzman M. Inhibition of tumor angiogenesis by cannabinoids. FASEB J. 2003, 17:529-531.
24. Blazquez C., Gonzalez-Feria L., Alvarez L., Haro A., Casanova M.L., Guzman M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res. 2004, 64:5617-5623.
25. Blazquez C., Salazar M., Carracedo A., Lorente M., Egia A., Gonzalez-Feria L., Haro A., Velasco G., Guzman M. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res. 2008, 68:1945-1952.
26. Böckmann S., Hinz B. Cannabidiol induces heme oxygenase-1 expression in human endothelial cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 2014, 387(Suppl. 1):S30.
27. Bolos V., Peinado H., Perez-Moreno M.A., Fraga M.F., Esteller M., Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J. Cell Sci. 2003, 116:499-511.
28. Braig S., Wallner S., Junglas B., Fuchshofer R., Bosserhoff A.K. CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration. Br. J. Cancer 2011, 105:231-238.
29. Brenneisen R., Egli A., Elsohly M.A., Henn V., Spiess Y. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int. J. Clin. Pharmacol. Ther. 1996, 34:446-452.
30. Brenneisen R., Meyer P., Chtioui H., Saugy M., Kamber M. Plasma and urine profiles of Delta9-tetrahydrocannabinol and its metabolites 11-hydroxy-Delta9-tetrahydrocannabinol and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes. Anal. Bioanal. Chem. 2010, 396:2493-2502.
31. Busch F.W., Seid D.A., Wei E.T. Mutagenic activity of marihuana smoke condensates. Cancer Lett. 1979, 6:319-324.
32. Caffarel M.M., Andradas C., Mira E., Perez-Gomez E., Cerutti C., Moreno-Bueno G., Flores J.M., Garcia-Real I., Palacios J., Manes S., Guzman M., Sanchez C. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol. Cancer 2010, 9:196.
33. Cantarella G., Scollo M., Lempereur L., Saccani-Jotti G., Basile F., Bernardini R. Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Biochem. Pharmacol. 2011, 82:380-388.
34. Caplan G.A., Brigham B.A. Marijuana smoking and carcinoma of the tongue. Is there an association?. Cancer 1990, 66:1005-1006.
35. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 2000, 6:389-395.
36. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 2003, 9:653-660.
37. Casanova M.L., Blazquez C., Martinez-Palacio J., Villanueva C., Fernandez-Acenero M.J., Huffman J.W., Jorcano J.L., Guzman M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest. 2003, 111:43-50.
38. Casanova M.L., Larcher F., Casanova B., Murillas R., Fernandez-Acenero M.J., Villanueva C., Martinez-Palacio J., Ullrich A., Conti C.J., Jorcano J.L. A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res. 2002, 62:3402-3407.
39. Cattaneo M., Fontanella E., Canton C., Delia D., Biunno I. SEL1L affects human pancreatic cancer cell cycle and invasiveness through modulation of PTEN and genes related to cell-matrix interactions. Neoplasia 2005, 7:1030-1038.
40. Chan P.C., Sills R.C., Braun A.G., Haseman J.K., Bucher J.R. Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam. Appl. Toxicol. 1996, 30:109-117.
41. Chan V.Y., Chan M.W., Leung W.K., Leung P.S., Sung J.J., Chan F.K. Intestinal trefoil factor promotes invasion in non-tumorigenic Rat-2 fibroblast cell. Regul. Pept. 2005, 127:87-94.
42. Charles A.G., Han T.Y., Liu Y.Y., Hansen N., Giuliano A.E., Cabot M.C. Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemother. Pharmacol. 2001, 47:444-450.
43. Chen A.L., Chen T.J., Braverman E.R., Acuri V., Kemer M., Varshavskiy M., Braverman D., Downs W.B., Blum S.H., Cassel K., Blum K. Hypothesizing that marijuana smokers are at a significantly lower risk of carcinogenicity relative to tobacco-non-marijuana smokers: evidenced based on statistical reevaluation of current literature. J. Psychoact. Drugs 2008, 40:263-272.
44. Cole S.P., Sparks K.E., Fraser K., Loe D.W., Grant C.E., Wilson G.M., Deeley R.G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994, 54:5902-5910.
45. Comelli F., Giagnoni G., Bettoni I., Colleoni M., Costa B. Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved. Phytother. Res. 2008, 22:1017-1024.
46. Consroe P., Kennedy K., Schram K. Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol. Biochem. Behav. 1991, 40:517-522.
47. Costantino C.M., Gupta A., Yewdall A.W., Dale B.M., Devi L.A., Chen B.K. Cannabinoid receptor 2-mediated attenuation of CXCR4-tropic HIV infection in primary CD4+ T cells. PloS One 2012, 7:e33961.
48. Crawford L.V., Pim D.C., Gurney E.G., Goodfellow P., Taylor-Papadimitriou J. Detection of a common feature in several human tumor cell lines-a 53,000-dalton protein. Proc. Natl. Acad. Sci. USA 1981, 78:41-45.
49. Curran S., Murray G.I. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur. J. Cancer 2000, 36:1621-1630.
50. Daling J.R., Doody D.R., Sun X., Trabert B.L., Weiss N.S., Chen C., Biggs M.L., Starr J.R., Dey S.K., Schwartz S.M. Association of marijuana use and the incidence of testicular germ cell tumors. Cancer 2009, 115:1215-1223.
51. De Petrocellis L., Bisogno T., Ligresti A., Bifulco M., Melck D., Di Marzo V. Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam. Clin. Pharmacol. 2002, 16:297-302.
52. De Petrocellis L., Davis J.B., Di Marzo V. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett. 2001, 506:253-256.
53. De Petrocellis L., Melck D., Palmisano A., Bisogno T., Laezza C., Bifulco M., Di Marzo V. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl. Acad. Sci. USA 1998, 95:8375-8380.
54. Deng X., He G., Levine A., Cao Y., Mullins C. Adenovirus-mediated expression of TIMP-1 and TIMP-2 in bone inhibits osteolytic degradation by human prostate cancer. Int. J. Cancer 2008, 122:209-218.
55. Deutsch D.G., Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 1993, 46:791-796.
56. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
57. Di Marzo V., Melck D., Orlando P., Bisogno T., Zagoory O., Bifulco M., Vogel Z., De Petrocellis L. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J. 2001, 358:249-255.
58. Dinnes J., Cave C., Huang S., Milne R. A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br. J. Cancer 2002, 86:501-505.
59. Dirks W.G., MacLeod R.A., Drexler H.G. ECV304 (endothelial) is really T24 (bladder carcinoma): cell line cross- contamination at source. In vitro Cell. Dev. Biol. Anim. 1999, 35:558-559.
60. Do Y., McKallip R.J., Nagarkatti M., Nagarkatti P.S. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-κB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J. Immunol. 2004, 173:2373-2382.
61. Donadelli M., Dando I., Zaniboni T., Costanzo C., Dalla Pozza E., Scupoli M.T., Scarpa A., Zappavigna S., Marra M., Abbruzzese A., Bifulco M., Caraglia M., Palmieri M. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis. 2011, 2:e152.
62. Donald P.J. Advanced malignancy in the young marijuana smoker. Adv. Exp. Med. Biol. 1991, 288:33-46.
63. Doyle L., Ross D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003, 22:7340-7358.
64. Dulak J., Łoboda A., Zagórska A., Józkowicz A. Complex role of heme oxygenase-1 in angiogenesis. Antioxid. Redox Signal. 2004, 6:858-866.
65. Duong T.D., Erickson C.A. MMP-2 plays an essential role in producing epithelial-mesenchymal transformations in the avian embryo. Dev. Dyn. 2004, 229:42-53.
66. Edlund M., Sung S.Y., Chung L.W. Modulation of prostate cancer growth in bone microenvironments. J. Cell. Biochem. 2004, 91:686-705.
67. Endocannabinoid Research Group, De Filippis D., D'Amico A., Cipriano M., Petrosino S., Orlando P., Di Marzo V., Iuvone T. Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. Pharmacol. Res. 2010, 61:321-328.
68. Endsley M.P., Thill R., Choudhry I., Williams C.L., Kajdacsy-Balla A., Campbell W.B., Nithipatikom K. Expression and function of fatty acid amide hydrolase in prostate cancer. Int. J. Cancer 2008, 123:1318-1326.
69. Farsandaj N., Ghahremani M.H., Ostad S.N. Role of cannabinoid and vanilloid receptors in invasion of human breast carcinoma cells. J. Environ. Pathol. Toxicol. Oncol. 2012, 31:377-387.
70. Feinshtein V., Erez O., Ben-Zvi Z., Erez N., Eshkoli T., Sheizaf B., Sheiner E., Huleihel M., Holcberg G. Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines. PeerJ 2013, 1:e153.
71. Feinshtein V., Erez O., Ben-Zvi Z., Eshkoli T., Sheizaf B., Sheiner E., Holcberg G. Cannabidiol enhances xenobiotic permeability through the human placental barrier by direct inhibition of breast cancer resistance protein: an ex vivo study. Am. J. Obstet. Gynecol. 2013, 209. 573 e571-573 e515.
72. Fiore E., Fusco C., Romero P., Stamenkovic I. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 2002, 21:5213-5223.
73. Fogli S., Nieri P., Chicca A., Adinolfi B., Mariotti V., Iacopetti P., Breschi M.C., Pellegrini S. Cannabinoid derivatives induce cell death in pancreatic MIAPaCa-2 cells via a receptor-independent mechanism. FEBS Lett. 2006, 580:1733-1739.
74. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
75. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 1972, 175:409-416.
76. Fong S., Debs R.J., Desprez P.Y. Id genes and proteins as promising targets in cancer therapy. Trends Mol. Med. 2004, 10:387-392.
77. Fong S., Itahana Y., Sumida T., Singh J., Coppe J.P., Liu Y., Richards P.C., Bennington J.L., Lee N.M., Debs R.J., Desprez P.Y. Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc. Natl. Acad. Sci. USA 2003, 100:13543-13548.
78. Foroughi M., Hendson G., Sargent M.A., Steinbok P. Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas-possible role of Cannabis inhalation. Childs Nerv. Syst. 2011, 27:671-679.
79. Fowler C.J., Josefsson A., Thors L., Chung S.C., Hammarsten P., Wikstrom P., Bergh A. Tumour epithelial expression levels of endocannabinoid markers modulate the value of endoglin-positive vascular density as a prognostic marker in prostate cancer. Biochim. Biophys. Acta 2013, 1831:1579-1587.
80. Franklin A., Stella N. Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors. Eur. J. Pharmacol. 2003, 474:195-198.
81. Freimuth N., Ramer R., Hinz B. Antitumorigenic effects of cannabinoids beyond apoptosis. J. Pharmacol. Exp. Ther. 2010, 332:336-344.
82. Fu J., Gaetani S., Oveisi F., Lo Verme J., Serrano A., Rodriguez De Fonseca F., Rosengarth A., Luecke H., Di Giacomo B., Tarzia G., Piomelli D. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature 2003, 425:90-93.
83. Fujihara T., Yashiro M., Inoue T., Sawada T., Kato Y., Ohira M., Nishiguchi Y., Ishikawa T., Sowa M., Chung K.H. Decrease in ICAM-1 expression on gastric cancer cells is correlated with lymph node metastasis. Gastric Cancer 1999, 2:221-225.
84. Galve-Roperh I., Rueda D., Gomez del Pulgar T., Velasco G., Guzman M. Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. Mol. Pharmacol. 2002, 62:1385-1392.
85. Galve-Roperh I., Sanchez C., Cortes M.L., Gomez del Pulgar T., Izquierdo M., Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med. 2000, 6:313-319.
86. Garcia A.G., Nedev H., Bijian K., Su J., Alaoui-Jamali M.A., Saragovi H.U. Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs. Oncogene 2013, 32:2527-2533.
87. Gillison M.L., D'Souza G., Westra W., Sugar E., Xiao W., Begum S., Viscidi R. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J. Natl. Cancer Inst. 2008, 100:407-420.
88. Gjerstorff M.F., Benoit V.M., Laenkholm A.V., Nielsen O., Johansen L.E., Ditzel H.J. Identification of genes with altered expression in medullary breast cancer vs. ductal breast cancer and normal breast epithelia. Int. J. Oncol. 2006, 28:1327-1335.
89. Gomez del Pulgar T., Velasco G., Sanchez C., Haro A., Guzman M. De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem. J. 2002, 363:183-188.
90. Good D.J., Polverini P.J., Rastinejad F., Le Beau M.M., Lemons R.S., Frazier W.A., Bouck N.P. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA 1990, 87:6624-6628.
91. Gordon M.D., Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J. Biol. Chem. 2006, 281:22429-22433.
92. Grant P., Gandhi P. A case of cannabis-induced pancreatitis. JOP: J. Pancreas 2004, 5:41-43.
93. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin. Pharmacokinet. 2003, 42:327-360.
94. Grzywacz M.J., Yang J.M., Hait W.N. Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide. Cancer Res. 2003, 63:2492-2498.
95. Guo C., Sah J.F., Beard L., Willson J.K., Markowitz S.D., Guda K. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes, Chromosomes Cancer 2008, 47:939-946.
96. Guzman M., Duarte M.J., Blazquez C., Ravina J., Rosa M.C., Galve-Roperh I., Sanchez C., Velasco G., Gonzalez-Feria L. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br. J. Cancer 2006, 95:197-203.
97. Guzman M., Sanchez C., Galve-Roperh I. Control of the cell survival/death decision by cannabinoids. J. Mol. Med. 2001, 78:613-625.
98. Hall W., Degenhardt L. Medical marijuana initiatives: are they justified? How successful are they likely to be?. CNS Drugs 2003, 17:689-697.
99. Hamano Y., Zeisberg M., Sugimoto H., Lively J.C., Maeshima Y., Yang C., Hynes R.O., Werb Z., Sudhakar A., Kalluri R. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 2003, 3:589-601.
100. Hamtiaux L., Hansoulle L., Dauguet N., Muccioli G.G., Gallez B., Lambert D.M. Increasing antiproliferative properties of endocannabinoids in N1E-115 neuroblastoma cells through inhibition of their metabolism. PloS One 2011, 6:e26823.
101. Hamtiaux L., Masquelier J., Muccioli G.G., Bouzin C., Feron O., Gallez B., Lambert D.M. The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action. BMC Cancer 2012, 12:92.
102. Hart S., Fischer O.M., Ullrich A. Cannabinoids induce cancer cell proliferation viatumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 2004, 64:1943-1950.
103. Hashibe M., Straif K., Tashkin D.P., Morgenstern H., Greenland S., Zhang Z.F. Epidemiologic review of marijuana use and cancer risk. Alcohol 2005, 35:265-275.
104. Hatva E., Kaipainen A., Mentula P., Jaaskelainen J., Paetau A., Haltia M., Alitalo K. Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am. J. Pathol. 1995, 146:368-378.
105. Haustein M., Ramer R., Linnebacher M., Manda K., Hinz B. Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Biochem. Pharmacol. 2014, 92:312-325.
106. Heljasvaara R., Nyberg P., Luostarinen J., Parikka M., Heikkila P., Rehn M., Sorsa T., Salo T., Pihlajaniemi T. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Exp. Cell Res. 2005, 307:292-304.
107. 2+ signaling and NFAT activation. FASEB J. 2009, 23:183-193.
108. Hernan Perez de la Ossa D., Lorente M., Gil-Alegre M.E., Torres S., Garcia-Taboada E., Aberturas Mdel R., Molpeceres J., Velasco G., Torres-Suarez A.I. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme. PloS One 2013, 8:e54795.
109. Herzig M., Savarese F., Novatchkova M., Semb H., Christofori G. Tumor progression induced by the loss of E-cadherin independent of beta-catenin/Tcf-mediated Wnt signaling. Oncogene 2007, 26:2290-2298.
110. Hilderbrandt S., Johnson I.J., Mukhopadhyay S. CB1 receptor and non-CB1/CB2 anandamide receptor mediated differential s-Nitrosylation of MMP: a novel angiogenic switch for the regulation of angiogenesis. Proceedings of the 18th Annual Symposium of Cannabinoids 2008, 17. International Cannabinoid Research Society, Burlington, VT.
111. Hinz B., Ramer R., Eichele K., Weinzierl U., Brune K. Up-regulation of cyclooxygenase-2 expression is involved in R(+)-methanandamide-induced apoptotic death of human neuroglioma cells. Mol. Pharmacol. 2004, 66:1643-1651.
112. Hoffmann D., Brunneman D.K., Gori G.B., Wynder E.L. On the carcinogenicity of marijuana smoke. Recent Adv. Phytochem. 1975, 9:3-81.
113. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., Yancopoulos G.D., Wiegand S.J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998.
114. Holland M.L., Allen J.D., Arnold J.C. Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur. J. Pharmacol. 2008, 591:128-131.
115. Holland M.L., Lau D.T., Allen J.D., Arnold J.C. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br. J. Pharmacol. 2007, 152:815-824.
116. Holland M.L., Panetta J.A., Hoskins J.M., Bebawy M., Roufogalis B.D., Allen J.D., Arnold J.C. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem. Pharmacol. 2006, 71:1146-1154.
117. Hooijberg J.H., Broxterman H.J., Kool M., Assaraf Y.G., Peters G.J., Noordhuis P., Scheper R.J., Borst P., Pinedo H.M., Jansen G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999, 59:2532-2535.
118. Huang H.C., Wang S.S., Hsin I.F., Chang C.C., Lee F.Y., Lin H.C., Chuang C.L., Lee J.Y., Hsieh H.G., Lee S.D. Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats. Hepatology 2012, 56:248-258.
119. Huggins J.P., Smart T.S., Langman S., Taylor L., Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 2012, 153:1837-1846.
120. Hughes S.E. Functional characterization of the spontaneously transformed human umbilical vein endothelial cell line ECV304: use in an in vitro model of angiogenesis. Exp. Cell Res. 1996, 225:171-185.
121. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
122. Iacovelli R., Alesini D., Palazzo A., Trenta P., Santoni M., De Marchis L., Cascinu S., Naso G., Cortesi E. Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer Treat. Rev. 2014, 40:271-275.
123. Izzo A.A., Aviello G., Petrosino S., Orlando P., Marsicano G., Lutz B., Borrelli F., Capasso R., Nigam S., Capasso F., Di Marzo V. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J. Mol. Med. 2008, 86:89-98. Endocannabinoid Research Group.
124. Jacobsson S.O., Rongard E., Stridh M., Tiger G., Fowler C.J. Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem. Pharmacol. 2000, 60:1807-1813.
125. Jacobsson S.O., Wallin T., Fowler C.J. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J. Pharmacol. Exp. Ther. 2001, 299:951-959.
126. Jain R.K. Molecular regulation of vessel maturation. Nat. Med. 2003, 9:685-693.
127. Jin X., Yin J., Kim S.H., Sohn Y.W., Beck S., Lim Y.C., Nam D.H., Choi Y.J., Kim H. EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res. 2011, 71:7125-7134.
128. Johns D.G., Behm D.J., Walker D.J., Ao Z., Shapland E.M., Daniels D.A., Riddick M., Dowell S., Staton P.C., Green P., Shabon U., Bao W., Aiyar N., Yue T.L., Brown A.J., Morrison A.D., Douglas S.A. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br. J. Pharmacol. 2007, 152:825-831.
129. Jorda M.A., Verbakel S.E., Valk P.J., Vankan-Berkhoudt Y.V., Maccarrone M., Finazzi-Agro A., Lowenberg B., Delwel R. Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood 2002, 99:2786-2793.
130. Juel-Jensen B.E. Cannabis and recurrent herpes simplex. Br. Med. J. 1972, 4:296.
131. Kaipainen A., Vlaykova T., Hatva E., Bohling T., Jekunen A., Pyrhonen S., Alitalo K. Enhanced expression of the tie receptor tyrosine kinase messenger RNA in the vascular endothelium of metastatic melanomas. Cancer Res. 1994, 54:6571-6577.
132. Kelly C.P., O'Keane J.C., Orellana J., Schroy P.C., Yang S., LaMont J.T., Brady H.R. Human colon cancer cells express ICAM-1 in vivo and support LFA-1-dependent lymphocyte adhesion in vitro. Am. J. Physiol. 1992, 263(6 Pt1):G864-G870.
133. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
134. Khasabova I.A., Khasabov S.G., Harding-Rose C., Coicou L.G., Seybold B.A., Lindberg A.E., Steevens C.D., Simone D.A., Seybold V.S. A decrease inanandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J. Neurosci. 2008, 28:11141-11152.
135. Khokha R., Waterhouse P., Yagel S., Lala P.K., Overall C.M., Norton G., Denhardt D.T. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science 1989, 243:947-950.
136. Khokha R., Zimmer M.J., Graham C.H., Lala P.K., Waterhouse P. Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells. J. Natl. Cancer Inst. 1992, 84:1017-1022.
137. Kiosses B.W., Tahir S.K., Kalnins V.I., Zimmerman A.M. The effects of delta-9-tetrahydrocannabinol on actin microfilaments. Cytobios 1990, 63:23-29.
138. Kishimoto S., Muramatsu M., Gokoh M., Oka S., Waku K., Sugiura T. Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. J. Biochem. 2005, 137:217-223.
139. Kleihues P., Louis D.N., Scheithauer B.W., Rorke L.B., Reifenberger G., Burger P.C., Cavenee W.K. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 2002, 61:215-225.
140. Kogan N.M., Blazquez C., Alvarez L., Gallily R., Schlesinger M., Guzman M., Mechoulam R. A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. Mol. Pharmacol. 2006, 70:51-59.
141. Kogan N.M., Rabinowitz R., Levi P., Gibson D., Sandor P., Schlesinger M., Mechoulam R. Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. J. Med. Chem. 2004, 47:3800-3806.
142. Kogan N.M., Schlesinger M., Priel E., Rabinowitz R., Berenshtein E., Chevion M., Mechoulam R. HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor. Mol. Cancer Ther. 2007, 6:173-183.
143. Kool M., van der Linden M., de Haas M., Scheffer G.L., de Vree J.M., Smith A.J., Jansen G., Peters G.J., Ponne N., Scheper R.J., Elferink R.P., Baas F., Borst P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. USA 1999, 96:6914-6919.
144. Krimpenfort P., Song J.Y., Proost N., Zevenhoven J., Jonkers J., Berns A. Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours. Nature 2012, 482:538-541.
145. Lacson J.C., Carroll J.D., Tuazon E., Castelao E.J., Bernstein L., Cortessis V.K. Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. Cancer 2012, 118:5374-5383.
146. Lauckner J.E., Jensen J.B., Chen H.Y., Lu H.C., Hille B., Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. USA 2008, 105:2699-2704.
147. Lauffenburger D.A., Horwitz A.F. Cell migration: a physically integrated molecular process. Cell 1996, 84:359-369.
148. Lee T.K., Poon R.T., Wo J.Y., Ma S., Guan X.Y., Myers J.N., Altevogt P., Yuen A.P. Lupeol suppresses cisplatin-induced nuclear factor-κB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res. 2007, 67:8800-8809.
149. Leelawat S., Leelawat K., Narong S., Matangkasombut O. The dual effects of delta(9)-tetrahydrocannabinol on cholangiocarcinoma cells: anti-invasion activity at low concentration and apoptosis induction at high concentration. Cancer Invest. 2010, 28:357-363.
150. Lefor A.T., Fabian D.F. Enhanced cytolytic activity of tumor infiltrating lymphocytes (TILs) derived from an ICAM-1 transfected tumor in a murine model. J. Surg. Res. 1998, 75:49-53.
151. Liang C., McClean M.D., Marsit C., Christensen B., Peters E., Nelson H.H., Kelsey K.T. A population-based case-control study of marijuana use and head and neck squamous cell carcinoma. Cancer Prev. Res. 2009, 2:759-768.
152. Ligresti A., Bisogno T., Matias I., De Petrocellis L., Cascio M.G., Cosenza V., D'Argenio G., Scaglione G., Bifulco M., Sorrentini I., Di Marzo V. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003, 125:677-687.
153. Ligresti A., Moriello A.S., Starowicz K., Matias I., Pisanti S., De Petrocellis L., Laezza C., Portella G., Bifulco M., Di Marzo V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exp. Ther. 2006, 318:1375-1387.
154. Lin C.Q., Singh J., Murata K., Itahana Y., Parrinello S., Liang S.H., Gillett C.E., Campisi J., Desprez P.Y. A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. Cancer Res. 2000, 60:1332-1340.
155. Lin Y.C., Shun C.T., Wu M.S., Chen C.C. A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin. Cancer Res. 2006, 12:7165-7173.
156. Ling M.T., Wang X., Zhang X., Wong Y.C. The multiple roles of Id-1 in cancer progression. Differ. Res. Biol. Divers. 2006, 74:481-487.
157. Liotta L.A., Tryggvason K., Garbisa S., Hart I., Foltz C.M., Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980, 284:67-68.
158. Llewellyn C.D., Johnson N.W., Warnakulasuriya K.A. Risk factors for oral cancer in newly diagnosed patients aged 45 years and younger: a case-control study in Southern England. J. Oral Pathol. Med. 2004, 33:525-532.
159. Lo Verme J., Fu J., Astarita G., La Rana G., Russo R., Calignano A., Piomelli D. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 2005, 67:15-19.
160. Lonardi S., Tosoni A., Brandes A.A. Adjuvant chemotherapy in the treatment of high grade gliomas. Cancer Treat. Rev. 2005, 31:79-89.
161. LoVerme J., Russo R., La Rana G., Fu J., Farthing J., Mattace-Raso G., Meli R., Hohmann A., Calignano A., Piomelli D. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J. Pharmacol. Exp. Ther. 2006, 319:1051-1061.
162. Maeda K., Kang S.M., Sawada T., Nishiguchi Y., Yashiro M., Ogawa Y., Ohira M., Ishikawa T., Hirakawa Y.S.C.K. Expression of intercellular adhesion molecule-1 and prognosis in colorectal cancer. Oncol. Rep. 2002, 9:511-514.
163. Maione S., De Petrocellis L., de Novellis V., Moriello A.S., Petrosino S., Palazzo E., Rossi F.S., Woodward D.F., Di Marzo V. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br. J. Pharmacol. 2007, 150:766-781.
164. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
165. McAllister S.D., Christian R.T., Horowitz M.P., Garcia A., Desprez P.Y. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol. Cancer Ther. 2007, 6:2921-2927.
166. McAllister S.D., Murase R., Christian R.T., Lau D., Zielinski A.J., Allison J., Almanza C., Pakdel A., Lee J., Limbad C., Liu Y., Debs R.J., Moore D.H., Desprez P.Y. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res. Treat. 2011, 129:37-47.
167. McCollum L., Howlett A.C., Mukhopadhyay S. Anandamide-mediated CB1/CB2 cannabinoid receptor-independent nitric oxide production in rabbit aortic endothelial cells. J. Pharmacol. Exp. Ther. 2007, 321:930-937.
168. McKallip R.J., Jia W., Schlomer J., Warren J.W., Nagarkatti P.S., Nagarkatti M. Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol. Pharmacol. 2006, 70:897-908.
169. McKallip R.J., Lombard C., Fisher M., Martin B.R., Ryu S., Grant S., Nagarkatti P.S., Nagarkatti M. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 2002, 100:627-634.
170. McKallip R.J., Lombard C., Martin B.R., Nagarkatti M., Nagarkatti P.S. Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J. Pharmacol. Exp. Ther. 2002, 302:451-465.
171. McKallip R.J., Nagarkatti M., Nagarkatti P.S. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J. Immunol. 2005, 174:3281-3289.
172. McPartland J.M., Matias I., Di Marzo V., Glass M. Evolutionary origins of the endocannabinoid system. Gene 2006, 370:64-74.
173. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 1995, 50:83-90.
174. Medveczky M.M., Sherwood T.A., Klein T.W., Friedman H., Medveczky P.G. Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro. BMC Med. 2004, 2:34.
175. Mehlen P., Puisieux A. Metastasis: a question of life or death. Nat. Rev. Cancer 2006, 6:449-458.
176. Melamede R. Cannabis and tobacco smoke are not equally carcinogenic. Harm Reduct. J. 2005, 2:21.
177. Melis M., Spatafora M., Melodia A., Pace E., Gjomarkaj M., Merendino A.M., Bonsignore G. ICAM-1 expression by lung cancer cell lines: effects of upregulation by cytokines on the interaction with LAK cells. Eur. Respir. J. 1996, 9:1831-1838.
178. Michalski C.W., Oti F.E., Erkan M., Sauliunaite D., Bergmann F., Pacher P., Batkai S., Muller M.W., Giese N.A., Friess H., Kleeff J. Cannabinoids in pancreaticcancer: correlation with survival and pain. Int. J. Cancer 2008, 122:742-750.
179. Mimeault M., Pommery N., Wattez N., Bailly C., Henichart J.P. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 2003, 56:1-12.
180. Miyake M., Fujimoto K., Anai S., Ohnishi S., Kuwada M., Nakai Y., Inoue T., Matsumura Y., Tomioka A., Ikeda T., Tanaka N., Hirao Y. Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladder. Oncol. Rep. 2011, 25:653-660.
181. Miyato H., Kitayama J., Yamashita H., Souma D., Asakage M., Yamada J., Nagawa H. Pharmacological synergism between cannabinoids and paclitaxel in gastric cancer cell lines. J. Surg. Res. 2009, 155:40-47.
182. Mo F.M., Offertaler L., Kunos G. Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. Eur. J. Pharmacol. 2004, 489:21-27.
183. Mole D.R., Blancher C., Copley R.R., Pollard P.J., Gleadle J.M., Ragoussis J., Ratcliffe P.J. Genome-wide association of hypoxia-inducible factor (HIF)-1α and HIF-2α DNA binding with expression profiling of hypoxia-inducible transcripts. J. Biol. Chem. 2009, 284:16767-16775.
184. Molina P.E., Winsauer P., Zhang P., Walker E., Birke L., Amedee A., Stouwe C.V., Troxclair D., McGoey R., Varner K., Byerley L., LaMotte L. Cannabinoid administration attenuates the progression of simian immunodeficiency virus. AIDS Res. Hum. Retroviruses 2011, 27:585-592.
185. Molnar J., Szabo D., Pusztai R., Mucsi I., Berek L., Ocsovszki I., Kawata E., Shoyama Y. Membrane associated antitumor effects of crocine-, ginsenoside- and cannabinoid derivates. Anticancer Res. 2000, 20:861-867.
186. Moody S.E., Sarkisian C.J., Hahn K.T., Gunther E.J., Pickup S., Dugan K.D., Innocent N., Cardiff R.D., Schnall M.D., Chodosh L.A. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2002, 2:451-461.
187. Mor M., Rivara S., Lodola A., Plazzi P.V., Tarzia G., Duranti A., Tontini A., Piersanti G., Kathuria S., Piomelli D. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J. Med. Chem. 2004, 47:4998-5008.
188. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
189. Munson A.E., Harris L.S., Friedman M.A., Dewey W.L., Carchman R.A. Antineoplastic activity of cannabinoids. J. Natl. Cancer Inst. 1975, 55:597-602.
190. Murase R., Kawamura R., Singer E., Pakdel A., Sarma P., Judkins J., Elwakeel E., Dayal S., Martinez-Martinez E., Amere M., Gujjar R., Mahadevan A., Desprez P.Y., McAllister S.D. Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. Br. J. Pharmacol. 2014, 171:4464-4477.
191. Murphy G., Gavrilovic J. Proteolysis and cell migration: creating a path?. Curr. Opin. Cell Biol. 1999, 11:614-621.
192. Nagarkatti P., Pandey R., Rieder S.A., Hegde V.L., Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med. Chem. 2009, 1:1333-1349.
193. Nahas G.G., Suciu-Foca N., Armand J.P., Morishima A. Inhibition of cellular mediated immunity in marihuana smokers. Science 1974, 183:419-420.
194. Nieri P., Romiti N., Adinolfi B., Chicca A., Massarelli I., Chieli E. Modulation of P-glycoprotein activity by cannabinoid molecules in HK-2 renal cells. Br. J. Pharmacol. 2006, 148:682-687.
195. Nishioka N., Matsuoka T., Yashiro M., Hirakawa K., Olden K., Roberts J.D. Linoleic acid enhances angiogenesis through suppression of angiostatin induced by plasminogen activator inhibitor 1. Br. J. Cancer 2011, 105:1750-1758.
196. Nithipatikom K., Endsley M.P., Isbell M.A., Falck J.R., Iwamoto Y., Hillard C.J., Campbell W.B. 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res. 2004, 64:8826-8830.
197. Nithipatikom K., Gomez-Granados A.D., Tang A.T., Pfeiffer A.W., Williams C.L., Campbell W.B. Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells. Endocrinology 2012, 153:29-41.
198. Nomura D.K., Lombardi D.P., Chang J.W., Niessen S., Ward A.M., Long J.Z., Hoover H.H., Cravatt B.F. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem. Biol. 2011, 18:846-856.
199. Nomura D.K., Long J.Z., Niessen S., Hoover H.S., Ng S.W., Cravatt B.F. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010, 140:49-61.
200. Novotny M., Merli F., Weisler M., Fencl M., Saeed T. Fractionation and capillary gas chromatographic-mass spectrometric characterization of the neutral components in marijuana and tobacco smoke condensates. J. Chromatogr. 1982, 238:141-150.
201. O'Reilly M.S., Wiederschain D., Stetler-Stevenson W.G., Folkman J., Moses M.A. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J. Biol. Chem. 1999, 274:29568-29571.
202. Oesch S., Walter D., Wachtel M., Pretre K., Salazar M., Guzman M., Velasco G., Schafer B.W. Cannabinoid receptor 1 is a potential drug target for treatmentof translocation-positive rhabdomyosarcoma. Mol. Cancer Ther. 2009, 8:1838-1845.
203. Offertaler L., Mo F.M., Batkai S., Liu J., Begg M., Razdan R.K., Martin B.R., Bukoski R.D., Kunos G. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol. Pharmacol. 2003, 63:699-705.
204. Ogawa Y., Hirakawa K., Nakata B., Fujihara T., Sawada T., Kato Y., Yoshikawa K., Sowa M. Expression of intercellular adhesion molecule-1 in invasive breast cancer reflects low growth potential, negative lymph node involvement, and good prognosis. Clin. Cancer Res. 1998, 4:31-36.
205. Oka S., Toshida T., Maruyama K., Nakajima K., Yamashita A., Sugiura T. 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J. Biochem. 2009, 145:13-20.
206. Okamoto H., Yatomi Y., Ohmori T., Satoh K., Matsumoto Y., Ozaki Y. Sphingosine 1-phosphate stimulates G(i)- and Rho-mediated vascular endothelial cell spreading and migration. Thrombosis Res. 2000, 99:259-265.
207. Oladipupo S., Hu S., Kovalski J., Yao J., Santeford A., Sohn R.E., Shohet R., Maslov K., Wang L.V., Arbeit J.M. VEGF is essential for hypoxia-inducible factor-mediated neovascularization but dispensable for endothelial sprouting. Proc. Natl. Acad. Sci. USA 2011, 108:13264-13269.
208. Ortiz-Barahona A., Villar D., Pescador N., Amigo J., del Peso L. Genome-wide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and in silico binding site prediction. Nucleic Acids Res. 2010, 38:2332-2345.
209. Pagotto U., Marsicano G., Fezza F., Theodoropoulou M., Grubler Y., Stalla J., Arzberger T., Milone A., Losa M., Di Marzo V., Lutz B., Stalla G.K. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J. Clin. Endocrinol. Metab. 2001, 86:2687-2696.
210. Park H.J., Lee H.J., Min H.Y., Chung H.J., Suh M.E., Park-Choo H.Y., Kim C., Kim H.J., Seo E.K., Lee S.K. Inhibitory effects of a benz[f]indole-4,9-dione analog on cancer cell metastasis mediated by the down-regulation of matrix metalloproteinase expression in human HT1080 fibrosarcoma cells. Eur. J. Pharmacol. 2005, 527:31-36.
211. Park M.J., Lee J.Y., Kwak H.J., Park C.M., Lee H.C., Woo S.H., Jin H.O., Han C.J., An S., Lee S.H., Chung H.Y., Park I.C., Hong S.I., Rhee C.H. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species. J. Cell. Biochem. 2005, 95:955-969.
212. Patel N., Kalra V.K. Placenta growth factor-induced early growth response 1 (Egr-1) regulates hypoxia-inducible factor-1alpha (HIF-1alpha) in endothelial cells. J. Biol. Chem. 2010, 285:20570-20579.
213. Perez-Gomez E., Andradas C., Flores J.M., Quintanilla M., Paramio J.M., Guzman M., Sanchez C. The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene 2013, 32:2534-2542.
214. Perren T.J., Swart A.M., Pfisterer J., Ledermann J.A., Pujade-Lauraine E., Kristensen G., Carey M.S., Beale P., Cervantes A., Kurzeder C., du Bois A., Sehouli J., Kimmig R., Stahle A., Collinson F., Essapen S., Gourley C., Lortholary A., Selle F., Mirza M.R., Leminen A., Plante M., Stark D., Qian W., Parmar M.K., Oza A.M., Investigators I. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 2011, 365:2484-2496.
215. Perry S.N., Johnson I.J., Mukhopadhyay S. Anandamide mediated angiogenesis: interplay between CB1 receptor and non CB1/CB2 anandamide receptor. Proceedings of the 16th Annual Symposium of Cannabinoids 2006, 61. International Cannabinoid Research Society, Burlington, VT.
216. Peters K.G., Coogan A., Berry D., Marks J., Iglehart J.D., Kontos C.D., Rao P., Sankar S., Trogan E. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br. J. Cancer 1998, 77:51-56.
217. Petersen G., Moesgaard B., Schmid P.C., Schmid H.H., Broholm H., Kosteljanetz M., Hansen H.S. Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumour brain tissue. J. Neurochem. 2005, 93:299-309.
218. Petrosino S., Di Marzo V. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr. Opin. Invest. Drugs 2010, 11:51-62.
219. Pineiro R., Maffucci T., Falasca M. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 2011, 30:142-152.
220. Pisanti S., Borselli C., Oliviero O., Laezza C., Gazzerro P., Bifulco M. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. J. Cell. Physiol. 2007, 211:495-503.
221. Pisanti S., Picardi P., Prota L., Proto M.C., Laezza C., McGuire P.G., Morbidelli L., Gazzerro P., Ziche M., Das A., Bifulco M. Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis. Blood 2011, 117:5541-5550.
222. Polen M.R., Sidney S., Tekawa I.S., Sadler M., Friedman G.D. Health care use by frequent marijuana smokers who do not smoke tobacco. West. J. Med. 1993, 158:596-601.
223. Portella G., Laezza C., Laccetti P., De Petrocellis L., Di Marzo V., Bifulco M. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J. 2003, 17:1771-1773.
224. Pourkhalili N., Ghahremani M.H., Farsandaj N., Tavajohi S., Majdzadeh M., Parsa M., Lavasani N.J., Ostad S.N. Evaluation of anti-invasion effect of cannabinoids on human hepatocarcinoma cells. Toxicol. Mech. Methods 2013, 23:120-126.
225. Powell E., Piwnica-Worms D., Piwnica-Worms H. Contribution of p53 to metastasis. Cancer Discov. 2014, 4:405-414.
226. Preet A., Ganju R.K., Groopman J.E. Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 2008, 27:339-346.
227. Preet A., Qamri Z., Nasser M.W., Prasad A., Shilo K., Zou X., Groopman J.E., Ganju R.K. Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. Cancer Prev. Res. 2011, 4:65-75.
228. Proto M.C., Gazzerro P., Di Croce L., Santoro A., Malfitano A.M., Pisanti S., Laezza C., Bifulco M. Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth. J. Cell. Physiol. 2012, 227:250-258.
229. Puri M.C., Rossant J., Alitalo K., Bernstein A., Partanen J. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J. 1995, 14:5884-5891.
230. Qamri Z., Preet A., Nasser M.W., Bass C.E., Leone G., Barsky S.H., Ganju R.K. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol. Cancer Ther. 2009, 8:3117-3129.
231. Quesada A.R., Munoz-Chapuli R., Medina M.A. Anti-angiogenic drugs: from bench to clinical trials. Med. Res. Rev. 2006, 26:483-530.
232. Quintavalle M., Elia L., Condorelli G., Courtneidge S.A. MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro. J. Cell Biol. 2010, 189:13-22.
233. Rajesh M., Mukhopadhyay P., Hasko G., Liaudet L., Mackie K., Pacher P. Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. Br. J. Pharmacol. 2010, 160:688-700.
234. Ramer R., Bublitz K., Freimuth N., Merkord J., Rohde H., Haustein M., Borchert P., Schmuhl E., Linnebacher M., Hinz B. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J. 2012, 26:1535-1548.
235. Ramer R., Eichele K., Hinz B. Upregulation of tissue inhibitor of matrix metalloproteinases-1 confers the anti-invasive action of cisplatin on human cancer cells. Oncogene 2007, 26:5822-5827.
236. Ramer R., Fischer S., Haustein M., Manda K., Hinz B. Cannabinoids inhibit angiogenic capacities of endothelial cells via release of tissue inhibitor of matrix metalloproteinases-1 from lung cancer cells. Biochem. Pharmacol. 2014, 91:202-216.
237. Ramer R., Heinemann K., Merkord J., Rohde H., Salamon A., Linnebacher M., Hinz B. COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells. Mol. Cancer Ther. 2013, 12:69-82.
238. Ramer R., Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J. Natl. Cancer Inst. 2008, 100:59-69.
239. Ramer R., Merkord J., Rohde H., Hinz B. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem. Pharmacol. 2010, 79:955-966.
240. Ramer R., Rohde A., Merkord J., Rohde H., Hinz B. Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells. Pharm. Res. 2010, 27:2162-2174.
241. Ramirez S.H., Hasko J., Skuba A., Fan S., Dykstra H., McCormick R., Reichenbach N., Krizbai I., Mahadevan A., Zhang M., Tuma R., Son Y.J., Persidsky Y. Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J. Neurosci. 2012, 32:4004-4016.
242. Reichenbach V., Ros J., Fernandez-Varo G., Casals G., Melgar-Lesmes P., Campos T., Makriyannis A., Morales-Ruiz M., Jimenez W. Prevention of fibrosis progression in CCl4-treated rats: role of the hepatic endocannabinoid and apelin systems. J. Pharmacol. Exp. Ther. 2012, 340:629-637.
243. Rosivatz E., Becker I., Specht K., Fricke E., Luber B., Busch R., Hofler H., Becker K.F. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am. J. Pathol. 2002, 161:1881-1891.
244. Roth M.D., Marques-Magallanes J.A., Yuan M., Sun W., Tashkin D.P., Hankinson O. Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. Am. J. Respir. Cell Mol. Biol. 2001, 24:339-344.
245. Ruan M., Ji T., Wu Z., Zhou J., Zhang C. Evaluation of expression of midkine in oral squamous cell carcinoma and its correlation with tumour angiogenesis. Int. J. Oral Maxillofac. Surg. 2007, 36:159-164.
246. Ruiz L., Miguel A., Diaz-Laviada I. Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett. 1999, 458:400-404.
247. Rundhaug J.E. Matrix metalloproteinases, angiogenesis, and cancer: commentary re: a. C. Lockhart etal., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res. 2003, 9:551-554.
248. Ryberg E., Larsson N., Sjogren S., Hjorth S., Hermansson N.O., Leonova J., Elebring T., Nilsson K., Drmota T., Greasley P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 2007, 152:1092-1101.
249. Saghatelian A., Trauger S.A., Want E.J., Hawkins E.G., Siuzdak G., Cravatt B.F. Assignment of endogenous substrates to enzymes by global metabolite profiling. Biochemistry 2004, 43:14332-14339.
250. Saharinen P., Alitalo K. The yin, the yang, and the angiopoietin-1. J. Clin. Invest. 2011, 121:2157-2159.
251. Salazar M., Carracedo A., Salanueva I.J., Hernandez-Tiedra S., Lorente M., Egia A., Vazquez P., Blazquez C., Torres S., Garcia S., Nowak J., Fimia G.M., Piacentini M., Cecconi F., Pandolfi P.P., Gonzalez-Feria L., Iovanna J.L., Guzman M., Boya P., Velasco G. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J. Clin. Invest. 2009, 119:1359-1372.
252. Salven P., Joensuu H., Heikkila P., Matikainen M.T., Wasenius V.M., Alanko A., Alitalo K. Endothelial Tie growth factor receptor provides antigenic marker for assessment of breast cancer angiogenesis. Br. J. Cancer 1996, 74:69-72.
253. Sampath J., Adachi M., Hatse S., Naesens L., Balzarini J., Flatley R.M., Matherly L.H., Schuetz J.D. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci 2002, 4:E14.
254. Sanchez C., de Ceballos M.L., Gomez del Pulgar T., Rueda D., Corbacho C., Velasco G., Galve-Roperh I., Huffman J.W., Ramon y Cajal S., Guzman M. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 2001, 61:5784-5789.
255. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., Johnson D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355:2542-2550.
256. Sarafian T.A., Magallanes J.A., Shau H., Tashkin D., Roth M.D. Oxidative stress produced by marijuana smoke. An adverse effect enhanced by cannabinoids. Am. J. Respir. Cell Mol. Biol. 1999, 20:1286-1293.
257. Sarker K.P., Obara S., Nakata M., Kitajima I., Maruyama I. Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Lett. 2000, 472:39-44.
258. Sartor W.M., Kyprianou N., Fabian D.F., Lefor A.T. Enhanced expression ofICAM-1 in a murine fibrosarcoma reduces tumor growth rate. J. Surg. Res. 1995, 59:66-74.
259. Sawada T., Kimura K., Nishihara T., Onoda N., Teraoka H., Yamashita Y., Yamada N., Yashiro M., Ohira M., Hirakawa K. TGF-beta1 down-regulates ICAM-1 expression and enhances liver metastasis of pancreatic cancer. Adv. Med. Sci. 2006, 51:60-65.
260. Schinkel A.H. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev. 1999, 36:179-194.
261. Schley M., Stander S., Kerner J., Vajkoczy P., Schupfer G., Dusch M., Schmelz M., Konrad C. Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. Brain Res. Bull. 2009, 79:333-337.
262. Schmid P.C., Wold L.E., Krebsbach R.J., Berdyshev E.V., Schmid H.H. Anandamide and other N-acylethanolamines in human tumors. Lipids 2002, 37:907-912.
263. Schmuhl E., Ramer R., Salamon A., Peters K., Hinz B. Increase of mesenchymal stem cell migration by cannabidiol via activation of p42/44 MAPK. Biochem. Pharmacol. 2014, 87:489-501.
264. Shayesteh L., Lu Y., Kuo W.L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G.B., Gray J.W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 1999, 21:99-102.
265. Solinas M., Massi P., Cantelmo A.R., Cattaneo M.G., Cammarota R., Bartolini D., Cinquina V., Valenti M., Vicentini L.M., Noonan D.M., Albini A., Parolaro D. Cannabidiol inhibits angiogenesis by multiple mechanisms. Br. J. Pharmacol. 2012, 167:1218-1231.
266. Solorzano C.C., Baker C.H., Bruns C.J., Killion J.J., Ellis L.M., Wood J., Fidler I.J. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother. Radiopharm. 2001, 16:359-370.
267. Song Z.H., Zhong M. CB1 cannabinoid receptor-mediated cell migration. J. Pharmacol. Exp. Ther. 2000, 294:204-209.
268. Sophocleous A., Landao-Bassonga E., Van't Hof R.J., Idris A.I., Ralston S.H. The type 2 cannabinoid receptor regulates bone mass and ovariectomy-induced bone loss by affecting osteoblast differentiation and bone formation. Endocrinology 2011, 152:2141-2149.
269. Soroceanu L., Murase R., Limbad C., Singer E., Allison J., Adrados I., Kawamura R., Pakdel A., Fukuyo Y., Nguyen D., Khan S., Arauz R., Yount G.L., Moore D.H., Desprez P.Y., McAllister S.D. Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res. 2013, 73:1559-1569.
270. Sparano J.A., Bernardo P., Stephenson P., Gradishar W.J., Ingle J.N., Zucker S., Davidson N.E. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J. Clin. Oncol. 2004, 22:4683-4690.
271. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin. Cancer Biol. 2000, 10:415-433.
272. Steder M., Alla V., Meier C., Spitschak A., Pahnke J., Furst K., Kowtharapu B.S., Engelmann D., Petigk J., Egberts F., Schad-Trcka S.G., Gross G., Nettelbeck D.M., Niemetz A., Putzer B.M. DNp73 exerts function in metastasis initiation by disconnecting the inhibitory role of EPLIN on IGF1R-AKT/STAT3 signaling. Cancer Cell 2013, 24:512-527.
273. Stetler-Stevenson W.G. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J. Clin. Invest. 1999, 103:1237-1241.
274. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002, 359:1011-1018.
275. Sticht G., Käferstein H. Grundbegriffe, Toxikokinetik und Toxikodynamik 1998, Gustav Fischer Verlag, Stuttgart.
276. Stratmann A., Risau W., Plate K.H. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am. J. Pathol. 1998, 153:1459-1466.
277. Su B., Cengizeroglu A., Farkasova K., Viola J.R., Anton M., Ellwart J.W., Haase R., Wagner E., Ogris M. Systemic TNFα gene therapy synergizes with liposomal doxorubicine in the treatment of metastatic cancer. Mol. Ther. 2013, 21:300-308.
278. Suda K., Rothen-Rutishauser B., Gunthert M., Wunderli-Allenspach H. Phenotypic characterization of human umbilical vein endothelial (ECV304) and urinary carcinoma (T24) cells: endothelial versus epithelial features. In vitro Cell. Dev. Biol. Anim. 2001, 37:505-514.
279. Sun Y., Alexander S.P., Kendall D.A., Bennett A.J. Cannabinoids and PPARα signalling. Biochem. Soc. Trans. 2006, 34:1095-1097.
280. Sunami T., Yashiro M., Chung K.H. ICAM-1 (intercellular adhesion molecule-1) gene transfection inhibits lymph node metastasis by human gastric cancer cells. Jpn. J. Cancer Res. 2000, 91:925-933.
281. Tashkin D.P. Smoked Marijuana as a Cause of Lung Injury. Monaldi Arch. Chest Dis. 2005, 63:93-100.
282. Tavazoie S.F., Alarcon C., Oskarsson T., Padua D., Wang Q., Bos P.D., Gerald W.L., Massague J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451:147-152.
283. Taylor F.M. Marijuana as a potential respiratory tract carcinogen: a retrospective analysis of a community hospital population. South. Med. J. 1988, 81:1213-1216.
284. Thapa D., Lee J.S., Heo S.W., Lee Y.R., Kang K.W., Kwak M.K., Choi H.G., Kim J.A. Novel hexahydrocannabinol analogs as potential anti-cancer agents inhibit cell proliferation and tumor angiogenesis. Eur. J. Pharmacol. 2011, 650:64-71.
285. Thors L., Bergh A., Persson E., Hammarsten P., Stattin P., Egevad L., Granfors T., Fowler C.J. Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. PloS One 2010, 5:e12275.
286. Tournier N., Chevillard L., Megarbane B., Pirnay S., Scherrmann J.M., Decleves X. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int. J. Neuropsychopharmacol. 2010, 13:905-915.
287. Trabert B., Sigurdson A.J., Sweeney A.M., Strom S.S., McGlynn K.A. Marijuana use and testicular germ cell tumors. Cancer 2011, 117:848-853.
288. Triozzi P.L., Eng C., Singh A.D. Targeted therapy for uveal melanoma. Cancer Treat. Rev. 2008, 34:247-258.
289. Turner J., Rhee J.G., Fabian D.F., Lefor A.T. Expression of ICAM-1 enhances in vivo lymphocyte adhesion in a murine fibrosarcoma. J. Surg. Oncol. 1997, 66:39-44.
290. Vaccani A., Massi P., Colombo A., Rubino T., Parolaro D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br. J. Pharmacol. 2005, 144:1032-1036.
291. Vanky F., Wang P., Patarroyo M., Klein E. Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro. Cancer Immunol. Immunother. 1990, 31:19-27.
292. Velasco G., Sanchez C., Guzman M. Towards the use of cannabinoids as antitumour agents. Nat. Rev. Cancer 2012, 12:436-444.
293. Vidinsky B., Gal P., Pilatova M., Vidova Z., Solar P., Varinska L., Ivanova L., Mojzis J. Anti-proliferative and anti-angiogenic effects of CB2R agonist (JWH-133) in non-small lung cancer cells (A549) and human umbilical vein endothelial cells: an in vitro investigation. Folia Biol. 2012, 58:75-80.
294. Wall M.E., Sadler B.M., Brine D., Taylor H., Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin. Pharmacol. Ther. 1983, 34:352-363.
295. Walsh D., Nelson K.A., Mahmoud F.A. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 2003, 11:137-143.
296. Walter L., Franklin A., Witting A., Wade C., Xie Y., Kunos G., Mackie K., Stella N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 2003, 23:1398-1405.
297. Watson S.J., Benson J.A., Joy J.E. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch. Gen. Psychiatry 2000, 57:547-552.
298. Westphal J.R., Van't Hullenaar R., Peek R., Willems R.W., Crickard K., Crickard U., Askaa J., Clemmensen I., Ruiter D.J., De Waal R.M. Angiogenic balancein human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int. J. Cancer 2000, 86:768-776.
299. Wittgen H.G., Greupink R., van den Heuvel J.J., van den Broek P.H., Dinter-Heidorn H., Koenderink J.B., Russel F.G. Exploiting transport activity of p-glycoprotein at the blood-brain barrier for the development of peripheral cannabinoid type 1 receptor antagonists. Mol. Pharm. 2012, 9:1351-1360.
300. Wittgen H.G., van den Heuvel J.J., van den Broek P.H., Dinter-Heidorn H., Koenderink J.B., Russel F.G. Cannabinoid type 1 receptor antagonists modulate transport activity of multidrug resistance-associated proteins MRP1, MRP2, MRP3, and MRP4. Drug Metab. Dispos. Biol. Fate Chem. 2011, 39:1294-1302.
301. Wright K., Rooney N., Feeney M., Tate J., Robertson D., Welham M., Ward S. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 2005, 129:437-453.
302. Wu T.C., Tashkin D.P., Djahed B., Rose J.E. Pulmonary hazards of smoking marijuana as compared with tobacco. N. Engl. J. Med. 1988, 318:347-351.
303. Xian X.S., Park H., Cho Y.K., Lee I.S., Kim S.W., Choi M.G., Chung I.S., Han K.H., Park J.M. Effect of a synthetic cannabinoid agonist on the proliferation and invasion of gastric cancer cells. J. Cell. Biochem. 2010, 110:321-332.
304. Xu J., Lamouille S., Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009, 19:156-172.
305. Yamai H., Sawada N., Yoshida T., Seike J., Takizawa H., Kenzaki K., Miyoshi T., Kondo K., Bando Y., Ohnishi Y., Tangoku A. Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo. Int. J. Cancer 2009, 125:952-960.
306. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., Rosenberg S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003, 349:427-434.
307. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., Savagner P., Gitelman I., Richardson A., Weinberg R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
308. Yang J., Mani S.A., Weinberg R.A. Exploring a new twist on tumor metastasis. Cancer Res. 2006, 66:4549-4552.
309. Yang H., Wang Z., Capo-Aponte J.E., Zhang F., Pan Z., Reinach P.S. Epidermal growth factor receptor transactivation by the cannabinoid receptor (CB1) and transient receptor potential vanilloid 1 (TRPV1) induces differential responses in corneal epithelial cells. Exp. Eye Res. 2010, 91:462-471.
310. Ye L., Zhang B., Seviour E.G., Tao K.X., Liu X.H., Ling Y., Chen J.Y., Wang G.B. Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer. Cancer Lett. 2011, 307:6-17.
311. Zacchigna S., Zentilin L., Morini M., Dell'Eva R., Noonan D.M., Albini A., Giacca M. AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo. Cancer Gene Ther. 2004, 11:73-80.
312. Zetter B.R. Angiogenesis and tumor metastasis. Annu. Rev. Med. 1998, 49:407-424.
313. Zhang X., Maor Y., Wang J.F., Kunos G., Groopman J.E. Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br. J. Pharmacol. 2010, 160:1583-1594.
314. Zhou B., Poon M.C., Pu W.T., Han Z.C. Therapeutic neovascularization for peripheral arterial diseases: advances and perspectives. Histol. Histopathol. 2007, 22:677-686.
315. Zhu H.J., Wang J.S., Markowitz J.S., Donovan J.L., Gibson B.B., Gefroh H.A., Devane C.L. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J. Pharmacol. Exp. Ther. 2006, 317:850-857.
316. Zhu L.X., Sharma S., Stolina M., Gardner B., Roth M.D., Tashkin D.P., Dubinett S.M. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J. Immunol. 2000, 165:373-380.
317. Zimmerman A.M., McClean D.K. Action of Narcotic and Hallucinogenic Agents on the Cell Cycle 1973, Academic Press, New York.
318. Zimmerman A.M., Stich H., San R. Nonmutagenic action of cannabinoids in vitro. Pharmacology 1978, 16:333-343.
319. Zirvi K.A., Najjar T.A., Slomiany B.L. Sensitivity of human colon tumor metastases to anticancer drugs in athymic (nude) mice. Cancer Lett. 1993, 72:39-44.
320. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., Julius D., Hogestatt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999, 400:452-457.